BioPharm International interviews Trevor Hallam, chief scientific officer at Sutro Biopharma. Posted Nov. 2011.
In this first of three podcast interviews, Dr. Hallam, chief scientific officer at Sutro Biopharma, introduces a non-traditional approach for expressing therapeutic proteins and peptides. More specifically, Sutro has developed a proprietary technology for manufacturing proteins in a cell-free system. The system uses a cell extract that contains the necessary machinery for producing protein without the need to maintain cell viability. Essentially, the bioreactor is the cell membrane for a giant cytosolic preparation. Dr. Hallam talks about the advantages of the system and even speculates as to future applications, for example, in a biodefense scenario. Posted Nov. 2011.
Related article on industrializing design, development, and manufacturing of therapeutic proteins
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.